Loading news...
Eversept Partners added 264,468 shares of Vera Therapeutics in the fourth quarter; the estimated transaction value was $9.39 million based on quarterly average pricing. Meanwhile, the quarter-end position value increased in value by $73.99 million, reflecting both trading and stock price movement.
Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million. Meanwhile, the quarter-end position value rose by $99.77 million, reflecting both the new shares held and price appreciation.
BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 46,000 shares of Class A common stock and restricted stock units (RSUs) underlying 25,875 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).
Vera Therapeutics, Inc. (VERA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christopher Hite, an accomplished executive with decades of corporate and financial strategy leadership experience in the biopharmaceutical sector, to Vera Therapeutics' Board of Directors.
Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of Medicine U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for atacicept with Prescription Drug User Fee Act (PDUFA) date of July 7, 2026; potential commercial launch of atacicept expected in mid-2026 Strong balance sheet bolstered by equity and debt financings in 2025 expected to be sufficient to fund company beyond atacicept approval and U.S. commercial launch BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the full year ended December 31, 2025.
BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.
Vera Therapeutics is downgraded from 'Strong Buy' to 'Hold' due to intensifying competition in the IgAN space. VERA's atacicept met the primary endpoint in the phase 3 ORIGIN trial, enabling a BLA submission and Priority Review with a PDUFA date of July 7, 2026. Competitive risks are heightened by Otsuka's VOYXACT, which shows superior proteinuria reduction and more convenient dosing.
BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 11,500 shares of Class A common stock and restricted stock units (RSUs) underlying 5,750 shares of Class A common stock to two (2) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).
Inventiva (NASDAQ: IVA - Get Free Report) and Vera Therapeutics (NASDAQ: VERA - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Analyst Recommendations This is a breakdown of current ratings
BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately.
SG Americas Securities LLC acquired a new stake in shares of Vera Therapeutics, Inc. (NASDAQ: VERA) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 31,345 shares of the company's stock, valued at approximately $911,000. Other large investors have
The consensus price target hints at a 53.1% upside potential for Vera Therapeutics (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Vera Therapeutics, Inc. (VERA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 228,750 shares of Class A common stock and restricted stock units (RSUs) underlying 116,000 shares of Class A common stock to eighteen (18) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).
The biotech has formally submitted a biologics license application to the FDA for its kidney disease drug. It has been accepted for priority review by the healthcare industry regulator.
Vera Therapeutics Inc. (NASDAQ: VERA) stock rose Wednesday after the U.S. Food and Drug Administration (FDA) accepted the company's atacicept Biologics License Application (BLA) for Priority Review.
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
Wells Fargo analysts believe a combination of tax refund spending, stronger earnings in lagging sectors, and fresh liquidity from the Federal Reserve could spark a “reflation” in equities. In a note led by strategist Ohsung Kwon, the investment firm said heavily shorted names in the “Russell 3000” may be particularly well-positioned for a rebound.
Vera Therapeutics, Inc. (NASDAQ: VERA - Get Free Report) Director Patrick Enright acquired 5,882 shares of the stock in a transaction dated Thursday, December 11th. The shares were purchased at an average cost of $42.50 per share, with a total value of $249,985.00. Following the completion of the purchase, the director owned 5,882 shares of the